Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Product

Terms/Details (Date)


Advanced Plant Pharmaceuticals Inc. (OTC BB:APPI)

Union Bless Ltd. (Hong Kong)

Sinusol

Distribution agreement for Union Bless to market and sell Advanced Plant's homeopathic allergy and sinus spray, Sinusol (8/19)

AlphaRx Inc. (OTC BB: ALRX)

Industria Farmaceutica Andromaco SA de C.V. (Mexico)

Indoflex

Industria will manufacture, sell, market and distribute Indoflex throughout Mexico (9/4)

Bioenvision Inc. (AMEX:BIV)

Stegram Pharmaceuticals Ltd. (UK)

Modrenal

Bioenvision obtained UK marketing rights to Modrenal to treat breast cancer (8/20)

CytoGenix Inc. (OTC BB: CYGX)

Phanuel Pursuits LLC (British Virgin Islands)

CytoGenix's anti-herpes topical cream

Phanuel gained an exclusive license for the manufacture and distribution of CytoGenix's anti-herpes topical cream in the People's Republic of China (8/26)

Cytos Biotechnology AG (Switzerland; SWX:CYTN)

Novartis AG (Switzerland)

Cytos' Immunodrugs

Novartis took a commercial license for Cytos' Immunodrugs against Alzheimer's disease; the event triggers an up-front payment, annual license fees and a milestone payment to Cytos (9/10)

Depomed Inc. (AMEX:DMI)

Elan Corp. plc (Ireland)

Gabapentin GR, a formulation of the seizure and pain drug

Depomed acquired all rights to the drug that uses its Gastric Retention delivery system, as Elan dropped out of their venture; Depomed would pay milestones and royalties if a product is commercialized (9/22)

Gilead Sciences Inc. (GILD)

Japan Tobacco Inc. (Japan)

Viread, Emtriva and a future co-formulation of the products

Licensing agreement in which Japan Tobacco will commercialize products in Gilead's HIV portfolio in Japan; Gilead will receive an up-front fee and could receive additional payments for milestones achieved; Japan Tobacco also would pay royalties (7/31)

Labopharm Inc. (Canada; TSE:DDS)

Esteve SA (Spain)

A once-daily version of the analgesic tramadol

Esteve will market the product in Spain and Portugal; Labopharm will receive payments for certain milestones through to regulatory approval, and will earn a share of revenue from product sales (8/5)

Labopharm Inc. (Canada; TSE:DDS)

Gruppo Angelini (Italy)

A once-daily version of the analgesic tramadol

Gruppo Angelini gained the exclusive right to market and sell the product in Italy and its related territories; Labopharm will supply Gruppo Angelini with finished packaged product through its European subsidiary (7/29)

Osiris Therapeutics Inc.*

JCR Pharmaceuticals Co. Ltd. (Japan)

A universal, adult mesenchymal stem cell technology

JCR gained exclusive Japanese rights to the technology for treating hematologic malignancies using hematopoietic stem cell transplants; Osiris received an up-front license fee and would receive milestone payments and royalties upon product launch (8/27)

Pozen Inc. (POZN)

Xcel Pharmaceuticals Inc.

MT 300

Xcel will commercialize MT 300 to treat migraines in the U.S.; Xcel is paying Pozen a $2M up-front fee and potential milestone payments of up to $8M due upon certain regulatory approvals and the achievement of a predetermined sales threshold; Xcel also would pay double-digit royalties (9/4)

Qiagen NV (the Netherlands; QGENF)

Novartis AG (Switzerland)

siRNA molecules

Qiagen will supply a genome-wide siRNA library to Novartis; financial terms were not disclosed (8/4)

Unigene Laboratories Inc. (OTC BB:UGNE)

Faran Laboratories SA (Greece)

Nasal calcitonin

Faran gained an exclusive license to sell the product in Greece, after it obtains European and pricing approvals; Unigene gets an up-front payment, potential milestones and a fixed fee for each unit received (9/23)

Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange.

No Comments